↓ Skip to main content

The ReSPonD trial - rivastigmine to stabilise gait in Parkinson’s disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients…

Overview of attention for article published in BMC Neurology, December 2013
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (87th percentile)
  • High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

news
1 news outlet
twitter
1 X user

Citations

dimensions_citation
24 Dimensions

Readers on

mendeley
161 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
The ReSPonD trial - rivastigmine to stabilise gait in Parkinson’s disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson’s disease who have fallen
Published in
BMC Neurology, December 2013
DOI 10.1186/1471-2377-13-188
Pubmed ID
Authors

Emily J Henderson, Stephen R Lord, Jacqueline CT Close, Andrew D Lawrence, Alan Whone, Yoav Ben-Shlomo

Abstract

Gait impairment is common in people with Parkinson's disease. There is a lack of effective interventions to target this debilitating complication and therefore a need to identify new therapeutic options. An underlying cholinergic deficit contributes to both the gait and cognitive dysfunction seen in Parkinson's disease. The combined impact of both impairments can be assessed in gait tasks performed with concomitant cognitive tasks. The aim of this trial is to evaluate the impact of a cholinesterase inhibitor on cognitive function and gait performance in people with established Parkinson's disease.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 161 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 <1%
United States 1 <1%
Unknown 159 99%

Demographic breakdown

Readers by professional status Count As %
Student > Master 23 14%
Student > Bachelor 22 14%
Student > Ph. D. Student 20 12%
Researcher 18 11%
Student > Postgraduate 10 6%
Other 23 14%
Unknown 45 28%
Readers by discipline Count As %
Medicine and Dentistry 42 26%
Psychology 14 9%
Neuroscience 14 9%
Nursing and Health Professions 13 8%
Biochemistry, Genetics and Molecular Biology 6 4%
Other 19 12%
Unknown 53 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 March 2021.
All research outputs
#3,108,628
of 22,733,113 outputs
Outputs from BMC Neurology
#376
of 2,425 outputs
Outputs of similar age
#37,973
of 306,782 outputs
Outputs of similar age from BMC Neurology
#12
of 74 outputs
Altmetric has tracked 22,733,113 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,425 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.7. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 306,782 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 74 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.